The Conversation (0)
Rosetta Genomics Ltd. (NASDAQ:ROSG) received a notice of allowance from the United States Patent and Trademark Office for a patent covering the method of use of a core element of Rosetta Genomics’ microRNA technology in identifying tumors of origin in cancer of unknown or uncertain primary and metastatic cancer. The patent application represents a key step towards protecting important elements of Rosetta’s microRNA technology.
Rosetta Genomics Ltd. (NASDAQ:ROSG) received a notice of allowance from the United States Patent and Trademark Office for a patent covering the method of use of a core element of Rosetta Genomics’ microRNA technology in identifying tumors of origin in cancer of unknown or uncertain primary and metastatic cancer. The patent application represents a key step towards protecting important elements of Rosetta’s microRNA technology.
As quoted in the press release:
The invention covered by this patent relates to the methods for determining an expression profile with a primer sequence and the comparison of the expression profile that quantitates 48 microRNAs and assigns one of 25 tumor diagnoses using a biologically motivated binary decision tree and a K-Nearest Neighbors classifier to identify the tumor of origin. This patent protects the intellectual property of the Company’s first generation Cancer Origin Test, which utilizes a polymerase chain reaction (PCR) technology for sequencing.
Rosetta Genomics CEO, Kenneth A. Berlin, said:
We are pleased to expand our intellectual property portfolio with this new U.S. patent. While this patent covers our first generation assay, it is still critical to our patent strategy as it creates a barrier to entry for would-be competitors and solidifies our position as the leader in microRNA biomarker technology and microRNA-based diagnostics
Click here to read the Rosetta Genomics, Ltd. (NASDAQ:ROSG) press release
